United States - English - NLM (National Library of Medicine)

jg pharma inc. - sulconazole nitrate (unii: 1t89100d5u) (sulconazole - unii:5d9haa5q5s) - sulconazole nitrate topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by trichophyton rubrum, trichophyton mentagrophytes, epidermophyton floccosum, and microsporum canis; and for the treatment of tinea versicolor. effectiveness has not been proven in tinea pedis (athlete's foot). symptomatic relief usually occurs within a few days after starting sulconazole nitrate topical solution and clinical improvement usually occurs within one week. sulconazole nitrate topical solution 1.0% is contraindicated in patients who have a history of hypersensitivity to any of the ingredients.

United States - English - NLM (National Library of Medicine)

jg pharma inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - severe recalcitrant nodular acne accutane is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, accutane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, accutane is indicated only for those patients who are not pregnant, because accutane can cause severe birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off accutane. the optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see warnings: skeletal: bone mineral density, hyperostosis, premature epiphyseal closure ). pregnancy: category x. see boxed contraindications and warnings. allergic reactions accutane is contraindicated in patients who are hypersensitive to this medication or to any of its components ( see precautions: hypersensitivity). accutane should not be given to patients who are sensitive to parabens, which are used as preservatives in the gelatin capsule.

United States - English - NLM (National Library of Medicine)

jg pharma inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - severe recalcitrant nodular acne accutane is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, accutane should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, accutane is indicated only for those patients who are not pregnant, because accutane can cause life-threatening birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off accutane. the optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see warnings: skeletal: bone mineral density, hyperostosis, premature epiphyseal closure ). pregnancy: category x. see boxed contraindications and warnings. allergic reactions accutane is contraindicated in patients who are hypersensitive to this medication or to any of its components ( see precautions: hypersensitivity).

United States - English - NLM (National Library of Medicine)

jg pharma - sulconazole nitrate (unii: 1t89100d5u) (sulconazole - unii:5d9haa5q5s) - sulconazole nitrate cream 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by trichophyton rubrum, trichophyton mentagro- phytes, epidermophyton floccosum , and microsporum canis ,* and for the treatment of tinea versicolor. sulconazole nitrate cream 1.0% is contraindicated in patients who have a history of hypersensitivity to any of its ingredients.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - azelnidipine - pale yellowish white tablet, diameter: 9.0 mm, thickness: 4.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - azelnidipine - pale yellowish white tablet, diameter: 7.0 mm, thickness: 3.4 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - l-carbocisteine - white tablet, diameter: 8.7 mm, thickness: 4.3 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - l-carbocisteine - white tablet, major axis: 15.9 mm, minor axis: 7.5 mm, thickness: 5.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - mecobalamin - very light red tablet, diameter: 7.1 mm, thickness: 4.0 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

kyosomirai pharma co., ltd. - mecobalamin - white tablet, diameter: 7.2 mm, thickness: 4.0 mm